DE3650175D1 - Synthetische antigene zum nachweis von aids. - Google Patents

Synthetische antigene zum nachweis von aids.

Info

Publication number
DE3650175D1
DE3650175D1 DE3650175T DE3650175T DE3650175D1 DE 3650175 D1 DE3650175 D1 DE 3650175D1 DE 3650175 T DE3650175 T DE 3650175T DE 3650175 T DE3650175 T DE 3650175T DE 3650175 D1 DE3650175 D1 DE 3650175D1
Authority
DE
Germany
Prior art keywords
synthetic antigens
aids
polypeptides
detect aids
detect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3650175T
Other languages
English (en)
Other versions
DE3650175T3 (de
DE3650175T2 (de
Inventor
Wesley Cosand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Rad Laboratories Inc
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3650175(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/767,303 external-priority patent/US4629783A/en
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of DE3650175D1 publication Critical patent/DE3650175D1/de
Application granted granted Critical
Publication of DE3650175T2 publication Critical patent/DE3650175T2/de
Anticipated expiration legal-status Critical
Publication of DE3650175T3 publication Critical patent/DE3650175T3/de
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE3650175T 1985-04-29 1986-04-21 Synthetische antigene zum nachweis von aids. Expired - Lifetime DE3650175T3 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US72805285A 1985-04-29 1985-04-29
US728052 1985-04-29
US06/767,303 US4629783A (en) 1985-04-29 1985-08-19 Synthetic antigen for the detection of AIDS-related disease
US767303 1985-08-19
US84448586A 1986-03-26 1986-03-26
US844485 1986-03-26
PCT/US1986/000831 WO1986006414A1 (en) 1985-04-29 1986-04-21 Synthetic antigens for the detection of aids-related disease

Publications (3)

Publication Number Publication Date
DE3650175D1 true DE3650175D1 (de) 1995-02-02
DE3650175T2 DE3650175T2 (de) 1995-06-14
DE3650175T3 DE3650175T3 (de) 2007-09-06

Family

ID=27419109

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3650175T Expired - Lifetime DE3650175T3 (de) 1985-04-29 1986-04-21 Synthetische antigene zum nachweis von aids.

Country Status (8)

Country Link
US (2) US6485900B1 (de)
EP (1) EP0220273B2 (de)
KR (1) KR910002374B1 (de)
AT (1) ATE116006T1 (de)
DE (1) DE3650175T3 (de)
DK (2) DK171250B1 (de)
FI (1) FI91073C (de)
WO (1) WO1986006414A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273695B1 (en) * 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
JP2702911B2 (ja) * 1985-09-11 1998-01-26 ユナイテツド・バイオメデイカル・インコ−ポレ−テツド 合成ペプチド、並びにそれを用いたエイズおよびプリ・エイズの検出方法
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
US7115363B1 (en) 1986-01-22 2006-10-03 Institut Pasteur Retrovirus capable of causing AIDS, means and methods for detecting it in vitro
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
FR2625100A2 (fr) * 1986-03-13 1989-06-30 Lurhuma Zirimwabagabo Utilisation d'antigenes pour la preparation de vaccins, proteine rendue immunogene et composition pharmaceutique la comportant
US5075211A (en) * 1986-03-26 1991-12-24 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4879212A (en) * 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
DK169582B1 (da) * 1986-06-23 1994-12-12 Squibb Bristol Myers Co Humant monoklonalt antistof, der er i stand til at reagere med en epitop på LAV/HTLV-III kappeglycoproteinet gp41, cellelinier, som producerer sådant antistof, farmaceutisk præparat indeholdende antistoffet samt fremgangsmåde til bestemmelse af nærværelsen af LAV/HTLV-III i en biologisk prøve og fremgangsmåde til separering af specifikke antigendeterminanter af LAV/HTLV-III under anvendelse af ant
US5087557A (en) * 1986-06-23 1992-02-11 Genetic Systems Corporation Human monoclonal antibody to lymphadenopathy-associated virus
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
EP0300031A4 (de) * 1987-01-28 1990-05-14 Ortho Pharma Corp Immunsuppressive peptide und verfahren zu ihrer anwendung.
CA1341436C (en) * 1987-03-25 2003-08-05 Wesley L. Cosand Synthetic antigens for the detection of aids-related disease caused by lav-2
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
SE8701628D0 (sv) * 1987-04-16 1987-04-16 Erling Norrby Medel for analys mm
US4921787A (en) * 1987-05-01 1990-05-01 Cambridge Bioscience Corporation Detection of antibodies to human immunodeficiency virus by agglutination of antigen coated latex
CA1339363C (en) * 1987-05-01 1997-08-26 Alan Ray Flesher Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
FI872409A0 (fi) * 1987-05-29 1987-05-29 Labsystems Oy Foerfarande foer detektering av hiv-1 motkroppar.
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
IE63455B1 (en) * 1987-09-04 1995-04-19 Int Murex Tech Corp Immunoassay and biological constructs for use therein
SE8704185L (sv) * 1987-10-28 1989-04-29 Ferring Ab Nya peptider, artificiella antigener och immunoanalystestsatser
US7442525B1 (en) * 1987-12-24 2008-10-28 Novartis Vaccines And Diagnostics, Inc. Method for expressing HIV polypeptides
SE8705197D0 (sv) * 1987-12-30 1987-12-30 Jonas Blomberg New peptides, two diagnostic methods using the peptides and a medicament based on the peptides
US6218102B1 (en) * 1988-01-27 2001-04-17 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6214537B1 (en) 1988-01-27 2001-04-10 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6210874B1 (en) 1988-01-27 2001-04-03 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US5241047A (en) * 1988-12-08 1993-08-31 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
EP0346022B1 (de) * 1988-06-10 1996-02-14 United Biomedical, Inc. Peptidfragmente von HIV
GB8828097D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
GB8828098D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
WO1991008227A1 (en) * 1989-11-27 1991-06-13 Replico Medical Aktiebolag NEW HIV-1 p17 PEPTIDES, DIAGNOSTIC ANTIGENS AND IMMUNOASSAY METHOD
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
US5480967A (en) * 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
FR2657017B1 (fr) * 1990-01-16 1995-08-18 Clonatec Sa Peptides derivant de la glycoproteine d'enveloppe du virus-hiv-1, leurs applications a la detection d'une infection due a ce virus et a la vaccination contre le sida.
ATE164853T1 (de) * 1990-01-16 1998-04-15 Orgenics Ltd Peptide, von virus-hiv-hüllen-glycoproteinen abstammend, deren verwendung zum nachweis einer infektion dieser viren und für die impfung gegen aids
SE468168B (sv) * 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
SE470074B (sv) * 1990-08-16 1993-11-01 Replico Medical Ab Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider
DE4039925A1 (de) * 1990-12-14 1992-06-17 Behringwerke Ag Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
US5686272A (en) * 1992-05-29 1997-11-11 Abbott Laboratories Amplification of RNA sequences using the ligase chain reaction
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2732346B1 (fr) * 1995-03-27 1997-05-30 Centre Nat Rech Scient Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FR2781158B1 (fr) 1998-07-15 2002-12-13 Vacs Internat Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
CA2676762C (en) * 1998-11-30 2015-12-29 Ortho-Clinical Diagnostics, Inc. Peptides for the detection of hiv-1 group o
FR2802426B1 (fr) 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
EP1466924B9 (de) * 2003-04-11 2013-06-19 Institut Pasteur Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
FR2882557A1 (fr) * 2005-02-25 2006-09-01 Centre Nat Rech Scient Epitopes de vih et composition pharmaceutique les contenant
JP6692834B2 (ja) 2015-02-09 2020-05-13 スリングショット バイオサイエンシーズ， インコーポレイテッド 調整可能な光学特性を有するヒドロゲル粒子およびその使用の方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8429099D0 (en) 1984-11-16 1984-12-27 Pasteur Institut Closed dna sequences
GB8324800D0 (en) 1983-09-15 1983-10-19 Pasteur Institut Antigens
FR2571968B1 (fr) 1984-10-18 1989-03-17 Pasteur Institut Virus purifie des lymphadenopathies et du syndrome d'immuno-depression acquise et antigenes d'enveloppe de ce virus, procede d'obtention de ce virus et de ces antigenes d'enveloppe de ce virus, applications de ce virus ou de ces antigenes a la preparation de compositions immunogenes ou pour le diagnostic des susdites affections.
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
GB8501473D0 (en) 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
DE3587181T2 (de) 1984-10-18 1993-06-24 Centre Nat Rech Scient F antigene vom menschlichen immunodefizienz-virus und deren verwendungen.
US4774175A (en) 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4784941A (en) 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4843011A (en) 1985-08-01 1989-06-27 Akzo N.V. Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production
US4803156A (en) * 1985-09-11 1989-02-07 New York Blood Center Peptide-beta-lactamase conjugates for enzyme-linked immunoassays
US4735896A (en) * 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
US4956273A (en) 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4753873A (en) 1986-02-03 1988-06-28 Cambridge Bioscience Corporation Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4808536A (en) 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US4879212A (en) 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US4957737A (en) 1986-05-27 1990-09-18 Hoffmann-La Roche Inc. HTLV-III (LAV) envelope peptides
US5017688A (en) 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US4861707A (en) 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
US4943628A (en) 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation

Also Published As

Publication number Publication date
FI865313A0 (fi) 1986-12-29
FI91073C (fi) 1994-05-10
US6214539B1 (en) 2001-04-10
EP0220273A4 (de) 1989-10-04
AU5773386A (en) 1986-11-18
DK626486A (da) 1986-12-23
DK626486D0 (da) 1986-12-23
KR880700080A (ko) 1988-02-15
WO1986006414A1 (en) 1986-11-06
DK84195A (da) 1995-07-18
EP0220273A1 (de) 1987-05-06
FI91073B (fi) 1994-01-31
FI865313A (fi) 1986-12-29
DK171250B1 (da) 1996-08-12
KR910002374B1 (ko) 1991-04-20
EP0220273B1 (de) 1994-12-21
ATE116006T1 (de) 1995-01-15
DE3650175T3 (de) 2007-09-06
AU597884B2 (en) 1990-06-14
US6485900B1 (en) 2002-11-26
EP0220273B2 (de) 2007-01-17
DE3650175T2 (de) 1995-06-14

Similar Documents

Publication Publication Date Title
DE3650175D1 (de) Synthetische antigene zum nachweis von aids.
ES8708058A1 (es) Un metodo para detectar la presencia de virus lav-htlv-iii o de anticuerpo para virus lav-htlv-iii
DE3752170D1 (de) Synthetisches Antigen zum Nachweis von mit AIDS in Zusammenhang stehenden Krankheiten
ATE90384T1 (de) Rekombinante virusproteine begleitet von lymphadenopathischem syndrom und/oder ''acquired immune deficiency syndrome'' (aids).
DE3788397T3 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
DE69030124D1 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus
DE3872754D1 (de) Nachweis von antikoerpern humaner immundefizienz-viren.
ATE109830T1 (de) Expression von virusproteinen mit immunologischer aktivität.
ATE128716T1 (de) Hiv-peptide und methoden für den nachweis von hiv.
ATE467690T1 (de) Synthetisches antigen zum nachweis von hiv- immunreaktiven antikörpern
DE3850593T3 (de) Synthetische Antigene zur Bestimmung der AIDS-bezogenen, von LAV-2 verursachten Krankheiten.
DE69028561D1 (de) Immunoassay zum Nachweis von Antikörpern gegen HIV
FI870501A (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut
ATE57262T1 (de) Verfahren zum nachweis von proteinen und viren.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: BIO-RAD LABORATORIES, INC., HERCULES, CALIF., US

8366 Restricted maintained after opposition proceedings